CHENQI TECH (09680) first half of the year: AI business drives a surge in technology service performance, contributing over 100 million in revenue, a growth of 274.4%.
On August 19, Qichi Travel (09680) announced its interim performance for 2026.
On August 19, CHENQI TECH (09680) released its mid-year performance report for 2026. During the reporting period, the company's revenue reached 4.035 billion RMB, a year-on-year increase of 140.7%. The total number of orders grew by 150.6% year-on-year to 184 million, with daily order volume exceeding one million.
In terms of profitability metrics, CHENQI TECH reported a significant increase in total gross profit of 156.3% to 500 million RMB, with a further enhancement in gross profit margin to 12.4%, and a substantial year-on-year improvement in profit of 45.2%. Both of its main businesses recorded growth in both revenue and gross profit. The transaction volume for mobility services reached 5.064 billion RMB, a year-on-year increase of 149.2%, while technology service revenue, primarily from AI data, exceeded 100 million RMB, with a year-on-year growth of 274.4%, achieving a gross profit margin of 22.7%.
According to the analysis of previously disclosed performance reports, technology services are contributing to rapid growth in new revenue for CHENQI TECH. Relevant revenue grew at a year-on-year rate of 175.8% in the first half of 2024, increasing to 207.0% in the first half of 2025, and further rising to 274.4% in the first half of 2026, indicating a clear trend of scale growth.
Related Articles

US Stock Market Move | Merck & Co., Inc. (MRK.US) and Moderna (MRNA.US) both saw their stock prices soar! The phase III trial of the personalized mRNA cancer vaccine was successful.

CONTINENTAL H (00513) plans to sell all shares of IQ Group for HKD 85 million, resuming trading on August 20.

Jiangsu Hengrui Pharmaceuticals (01276): Liu Xiaohan resigns as joint company secretary.
US Stock Market Move | Merck & Co., Inc. (MRK.US) and Moderna (MRNA.US) both saw their stock prices soar! The phase III trial of the personalized mRNA cancer vaccine was successful.

CONTINENTAL H (00513) plans to sell all shares of IQ Group for HKD 85 million, resuming trading on August 20.

Jiangsu Hengrui Pharmaceuticals (01276): Liu Xiaohan resigns as joint company secretary.

RECOMMEND





